Research Article

      Abstract    

        

HOME

STUDY OF TROPONIN-I LEVELS IN COVID-19 PATIENTS

 

 S Rukwal, H Kaur, P Kaur, M Shrivastava     

 

ABSTRACT: BACKGROUND AND OBJECTIVES: Elevated Troponin-I levels either due to direct or indirect cardiac injury can present as asymptomatic to fulminant myocarditis and circulatory shock in COVID-19 patients. Our objective is to evaluate the Troponin-I levels in covid patients. AIM: To evaluate the possible myocardial involvement in covid-19 patients with the help of Troponin-I levels as an indicator of cardiac injury and its prognostic implication and significance as it is associated with increased mortality in patients with COVID-19. METHORDS: This was a both a prospective and retrospective cohort study done from 1st January 2021 to 1st July 2021. A total of 240 admitted patients were included and whose Troponin-I levels were evaluated and in a comparative analysis was performed for the demography, clinical features, biochemical markers and their outcome with their Troponin-I levels. RESULTS: Out of 250 covid-19 positive hospitalized patients, 15patients have elevated Troponin-I levels. Among these 15 patients 60% had preexisting co morbidities like hypertension, diabetes and history of cardiac disease. Patients with elevated troponin level had mean age of 61.1years, length of stay was >14 days in 60% patients. In 46% patients Troponin-I levels were more than 200ng/L. These patients had a higher need for intensive care with mortality of 73%.  CONCLUSION: Etiology of myocardial involvement is multifactorial. Our study also concluded that elevated troponin levels in patients with covid19 have high morality. Therefore, the measurement of cardiac biomarkers, including Troponin-I and brain natriuretic peptide (BNP), should be performed on admission.

 

KEYWORD:  Myocarditis, Troponin-I, co morbidities, Covid-19.

REFERENCES:

  1. [1] Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of Cardiac Injury with Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 1;5,7:802-810.

  2. [2] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382,8:727-733.

  3. [3] Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 323,11: 1061–1069.

  4. [4] Mattiuzzi C, Lippi G. Which lessons shall we learn from the 2019 novel coronavirus outbreak? Ann Transl Med. 2020;8,3:48.

  5. [5] Ruan Q, Yang K, Wang W, Jiang L, Song J.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.  Intensive Care Med. 2020;46,5:846-848.

  6. [6] Bavishi C, Bonow RO, Trivedi V, Abbott JD, Messerli FH, Bhatt DL. Acute myocardial injury in patients hospitalized with COVID-19 infection: a review. Prog Cardiovasc Dis. 2020; S0033-0620,20:30123-7.

  7. [7] Bavishi C, Bonow RO, Trivedi V, Abbott JD, Messerli FH, Bhatt DL. Acute myocardial injury in patients hospitalized with COVID-19 infection: a review. Prog Cardiovasc Dis. 2020; S0033-0620,20:30123-7.

  8. [8] Lang JP, Wang X, Moura FA, Siddiqi HK, Morrow DA, Bohula EA. A current review of COVID-19 for the cardiovascular specialist. Am Heart J. 2020; 226:29-44.

  9. [9] Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated Troponin in Patients with Coronavirus Disease 2019: Possible Mechanisms. J Card Fail. 2020;26,6:470-475

  10. [10] Bavishi, C., Bonow, R. O., Trivedi, V., Abbott, J. D., Messerli, F. H., & Bhatt, D. L. (2020). Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. Progress in cardiovascular diseases, 63,5, 682–689.

  11. [11] Santoso A, Pranata R, Wibowo A, Al-Farabi MJ, Huang I, Antariksa B. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis. Am J Emerg Med. 2021; 44:352-357

  12. [12] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181,2:271-280.e8.

  13. [13] Qian Z, Travanty EA, Oko L, Edeen K, Berglund A, Wang J, Ito Y, Holmes KV, Mason RJ. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. Am J Respir Cell Mol Biol. 2013;48,6:742-8.

  14. [14] Goulter AB, Goddard MJ, Allen JC, Clark KL. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2004;19; 2:19. 

  15. [15] Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004 ;203,2:631-7.

  16. [16] Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., & Tan, W. (2020). Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA, 323,18: 1843–1844

  17. [17] Wei ZY, Qian HY. Myocardial injury in patients with COVID-19 pneumonia. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 2;48(0): E006.

  18. [18] Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today. 1996;17,5:214-7.

  19. [19] Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2021;51,4:1107-1110. 

  20. [20] Schmitt FCF, Manolov V, Morgenstern J, Fleming T, Heitmeier S, Uhle F, Al-Saeedi M, Hackert T, Bruckner T, Schöchl H, Weigand MA, Hofer S, Brenner T. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care. 2019;9,1:19.

  21. [21] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 ;8,5:475-481

  22. [22] Integrated surveillance of COVID-19 in Italy. Published March 22, 2020. Accessed March 30, 2020.

  23. [23] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 ;395,10223:497-506.

  24. [24] Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of Cardiac Injury with Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5,7:802-810.

  25. [25] Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. Published online February 28, 2020.

  26. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18,4:844-847.

 To cite this article:

Rukwal S, H Kaur H, Kaur P, Shrivastava M. Study of Troponin-I levels in Covid-19 patients. Int. J. Med. Lab. Res. 2022; 7,1:11-19. http://doi.org/10.35503/IJMLR.2022.72